Christian Schürch

Title: Christian Schürch: Innovator in Cancer Therapy

Introduction

Christian Schürch is a notable inventor based in Spiegel bei Bern, Switzerland. He has made significant contributions to the field of cancer therapy, particularly in the treatment of BCR-ABL1 related disorders such as chronic myelogenous leukemia. With a total of 2 patents, Schürch's work is paving the way for innovative therapeutic approaches.

Latest Patents

His latest patents include the "Anti-CD70 and BCR-ABL inhibitor combination therapy," which provides methods and compositions for treating BCR-ABL1 related disorders. This therapy utilizes a combination of a WNT signaling pathway inhibitor and a BCR-ABL1 tyrosine kinase inhibitor. Another significant patent is the "Anti-CD70 combination therapy," which also focuses on the treatment of BCR-ABL1 related disorders using similar therapeutic combinations.

Career Highlights

Christian Schürch is affiliated with the University of Bern, where he continues to advance research in cancer therapies. His innovative approaches have garnered attention in the medical community, contributing to the development of effective treatment options for patients.

Collaborations

Some of his notable coworkers include Carsten Riether and Adrian Ochsenbein, who collaborate with him on various research projects aimed at improving cancer treatment methodologies.

Conclusion

Christian Schürch's contributions to cancer therapy through his patents and research at the University of Bern highlight his role as an influential inventor in the medical field. His work continues to inspire advancements in the treatment of chronic myelogenous leukemia and related disorders.